Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| African Trypanosomiasis Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for African Trypanosomiasis Overview | 8 | 1 |
| Pipeline Products for African Trypanosomiasis Comparative Analysis | 9 | 1 |
| African Trypanosomiasis Therapeutics under Development by Companies | 10 | 1 |
| African Trypanosomiasis Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| African Trypanosomiasis Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| African Trypanosomiasis Products under Development by Companies | 15 | 1 |
| African Trypanosomiasis Products under Investigation by Universities/Institutes | 16 | 1 |
| African Trypanosomiasis Companies Involved in Therapeutics Development | 17 | 3 |
| Novartis AG | 17 | 1 |
| Sanofi | 18 | 1 |
| Scynexis, Inc. | 19 | 1 |
| African Trypanosomiasis Therapeutics Assessment | 20 | 8 |
| Assessment by Monotherapy Products | 20 | 1 |
| Assessment by Target | 21 | 2 |
| Assessment by Mechanism of Action | 23 | 2 |
| Assessment by Route of Administration | 25 | 1 |
| Assessment by Molecule Type | 26 | 2 |
| Drug Profiles | 28 | 15 |
| AN-5568 Drug Profile | 28 | 2 |
| DDD-100097 Drug Profile | 30 | 1 |
| fexinidazole Drug Profile | 31 | 2 |
| GNF-6702 Drug Profile | 33 | 1 |
| melarsoprol hydroxypropylbetadex Drug Profile | 34 | 1 |
| Peptides for Sleeping Sickness Drug Profile | 35 | 1 |
| Small Molecules for African Trypanosomiasis Drug Profile | 36 | 1 |
| Small Molecules for African Trypanosomiasis and Infectious Diseases Drug Profile | 37 | 1 |
| Small Molecules for Infectious Diseases Drug Profile | 38 | 1 |
| Small Molecules for Protozoal Infections Drug Profile | 39 | 1 |
| Small Molecules for Sleeping Sickness Drug Profile | 40 | 1 |
| Small Molecules to Inhibit Leucyl-tRNA Synthetase (LeuRS) for Human African Trypanosomiasis Drug Profile | 41 | 1 |
| Small Molecules to Inhibit N-Myristoyltransferase for African Trypanosomiasis Drug Profile | 42 | 1 |
| African Trypanosomiasis Dormant Projects | 43 | 1 |
| African Trypanosomiasis Discontinued Products | 44 | 1 |
| African Trypanosomiasis Product Development Milestones | 45 | 3 |
| Featured News &Press Releases | 45 | 1 |
| Sep 08, 2015: Clinical trial for first oral drug candidate specifically developed for sleeping sickness | 45 | 1 |
| Mar 12, 2012: Anacor Announces Commencement Of Phase I Clinical Trials Of Boron-Based Compound For Sleeping Sickness | 45 | 1 |
| Jun 28, 2011: Anacor Pharmaceuticals Partnership Advances New Drug Candidate To Combat Sleeping Sickness | 46 | 2 |
| Appendix | 48 | 2 |
| Methodology | 48 | 1 |
| Coverage | 48 | 1 |
| Secondary Research | 48 | 1 |
| Primary Research | 48 | 1 |
| Expert Panel Validation | 48 | 1 |
| Contact Us | 48 | 1 |
| Disclaimer | 49 | 1 |
